Victoria Johnson on Muck Rack

Victoria Johnson

Verified
Freehold
As seen in: HCP Live, The Washington Post, Wiley Online Library, MDPI, Scientific American, Pediatrics, EIN News, MPR News (Saint Paul, MN), NewsBreak, KSWB-TV (San Diego, CA), nybg.org and
Reporting on rheumatology for @HCPLiveNews vjohnson@mjhlifesciences.com 📧 | Tweets my own ✍️ 🇵🇭
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Victoria

Contact Victoria, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA Approves BGF Triple Therapy for Asthma in Patients 12 and Older

|
By Victoria Johnson Verified
| consultantlive.com
The United States Food and Drug Administration (US FDA) has approved budesonide/glycopyrrolate/formoterol fumarate (BGF; BREZTRI Aerosphere, AstraZeneca) as the first single-inhaler triple-combination maintenance therapy for asthma in adult and pediatric patients 12 years of age and older, the company announced April 28, 2026.
Open in Who Shared View Duplicates (3) Issue with article?

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

|
By Victoria Johnson Verified
| consultantlive.com
The United States (US) Food and Drug Administration (FDA) has granted accelerated approval to navepegritide (YUVIWEL), a once-weekly C-type natriuretic peptide (CNP) analog, to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses.
Open in Who Shared View Duplicates (2) Issue with article?

AAAAI Annual Meeting 2026 Preview: 5 Trials to Know

|
By Victoria Johnson Verified
| consultantlive.com
When the American Academy of Allergy, Asthma & Immunology (AAAAI) convenes for its 2026 Annual Meeting in Philadelphia from February 27 to March 2, the specialty will gather at a moment defined by both therapeutic expansion and biologic refinement.
Open in Who Shared View Duplicates (2) Issue with article?
See all 1,136 licensed articles (2,497 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified